Comparative Pharmacology
Head-to-head clinical analysis: LEVONEST versus SYEDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONEST versus SYEDA.
LEVONEST vs SYEDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.
Syeda is a combination of drospirenone and ethinyl estradiol, a contraceptive that suppresses gonadotropins, primarily inhibiting ovulation; drospirenone has antimineralocorticoid and antiandrogenic activity.
One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.
1 tablet (3 mg drospirenone / 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
The terminal elimination half-life is approximately 24-30 hours. This relatively long half-life supports once-daily dosing and allows for stable plasma concentrations within 5-7 days of continuous use.
Terminal elimination half-life of 12-15 hours; allows twice-daily dosing for sustained therapeutic levels.
Renal excretion of conjugated metabolites accounts for approximately 60-80% of an administered dose; fecal elimination via bile accounts for 20-40%.
Urinary excretion (40-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for 15-25%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive